Skip to main content

eTheRNA collects €34M for mRNA vaccines

  • June 16, 2020

VUB spin-off eTheRNA received €34 million to bankroll the development of its mRNA technologies, as well as a suite of mRNA immunotherapies for cancer and infectious diseases, including a program against SARS-CoV-2, the virus that causes COVID-19.

Read more in De Tijd, Trends and VUB Today